查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1553708

美国雾化器市场规模、份额、趋势分析报告：按类型、按应用、按最终用途、细分市场预测，2024-2030 年

U.S. Nebulizer Market Size, Share & Trends Analysis Report By Type (Jet, Mesh, Ultrasonic), By Application (COPD, Asthma), By End-use (Hospitals & Clinics, Emergency Centers), And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 70 Pages | 商品交期: 2-10个工作天内

价格
简介目录

美国雾化器市场成长与趋势

Grand View Research, Inc.最新报告显示，到2030年，美国雾化器市场规模预计将达到4.126亿美元，预测期内复合年增长率为5.4%。

美国慢性呼吸道疾病盛行率上升、对居家医疗设备的需求增加以及老年人口的增加是推动市场成长的关键因素。

慢性呼吸道疾病盛行率上升是市场成长的关键驱动力。根据美国疾病管制与预防中心（CDC）发布的统计数据，美国约有1,840万成年人美国气喘。据 CDC 称，2014 年，慢性阻塞性肺病(COPD) 估计是美国第三大死亡原因，当年约有 1570 万美国被诊断出患有该疾病。过量摄取烟酒、不健康饮食、缺乏运动和惊人的肥胖率等因素也可能导緻美国呼吸道疾病发病率上升，并促进雾化器市场在预测期内的增长。

近年来，居家医疗设备受到欢迎，市场占有率不断扩大。美国老年人口的不断增加、目标疾病的高发病率以及控制医疗费用的需求不断增长，预计将成为推动居家医疗器材普及的因素。居家医疗是替代昂贵住院治疗的一种经济有效的选择。适合家庭使用的紧凑型雾化器现已上市，雾化器技术的创新降低了噪音并增加了功能，从而在居家医疗中得到越来越多的采用。此外，保险公司等第三方付款人也支援此类设备，因为他们的目标是在提供优质医疗服务的同时降低成本。预计这些因素也将有助于市场成长。

美国雾化器市场报告亮点

  • 与常规雾化器相比，Mesh 是一种先进技术，可提供快速、高效的药物输送，因此预计在预测期内的复合年增长率将达到 5.8%。
  • 2023年，气喘细分市场占据主导地位，占据40.0%的市场占有率。气喘发生率很高，需要定期有效地服用药物来控制疾病。
  • 2023年，医院和诊所市场将主导市场。医院和诊所描述了受控环境，医生经过培训可以透过雾化器给药，特别是对于重症患者或需要加护治疗的患者。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章美国雾化器市场变数、趋势、范围

  • 市场介绍/系统展望
  • 市场规模及成长前景
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 美国雾化器市场分析工具
    • 波特的分析
    • PESTEL分析

第四章美国雾化器市场：按类型、估计和趋势分析

  • 细分仪表板
  • 美国雾化器市场：类型变化分析，2023 年和 2030 年
  • 喷射
  • 网
  • 超音波

第五章美国雾化器市场：按应用、估计和趋势分析

  • 细分仪表板
  • 美国雾化器市场：2023 年和 2030 年应用变化分析
  • 慢性阻塞性肺病
  • 气喘
  • 其他的

第六章美国雾化器市场：依最终用途、估计和趋势分析

  • 细分仪表板
  • 美国雾化器市场：2023 年和 2030 年最终用途变化分析
  • 医院和诊所
  • 急诊中心
  • 其他的

第七章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司分类
  • 企业热力图分析
  • 公司简介
    • OMRON Healthcare, Inc.
    • GE Healthcare
    • Koninklijke Philips NV
    • Allied Healthcare
    • Vectura Group Plc.
    • PARI Respiratory Equipment, Inc.
    • Aerogen
    • DeVilbiss Healthcare LLC
    • Briggs Healthcare
    • Beurer GmBH
简介目录
Product Code: GVR-2-68038-085-9

U.S. Nebulizer Market Growth & Trends:

The U.S. nebulizer market size is anticipated to reach USD 412.6 million by 2030, according to a new report by Grand View Research, Inc., expanding at a 5.4% CAGR during the forecast period. Rising incidence of chronic respiratory diseases in U.S., increasing demand for home healthcare devices, and growing geriatric population are among the key factors driving market growth.

Rising incidence of chronic respiratory diseases is a crucial driver for market growth. According to statistics published by the Centers for Disease Control and Prevention (CDC), approximately 18.4 million adults in U.S. suffer from asthma. Chronic obstructive pulmonary disease (COPD) was estimated to be the third leading cause of death in the country in 2014, according to the CDC, with around 15.7 million Americans diagnosed with the condition that year. Factors such as overconsumption of tobacco and alcohol, unhealthy diet, lack of physical activity, and alarming rates of obesity are also likely to lead to an increase in incidence of respiratory disorders in U.S., contributing to the growth of the nebulizer market over the forecast period.

Home healthcare devices have been gaining popularity and market share in recent years. Growing geriatric population in U.S., high incidence of target diseases, and rising need to curb healthcare expenditure are expected to be some of the high-impact rendering drivers for home healthcare devices. Home healthcare is a cost-effective alternative to expensive hospital stays. Easy availability of compact nebulizers ideal for home use and technological innovations in nebulizers to reduce noise and improve functionality are increasing their adoption in home healthcare. Moreover, third-party payers, such as insurance companies, favor such devices as they aim to reduce costs while providing quality healthcare services. Such factors are also expected to contribute to market growth.

U.S. Nebulizer Market Report Highlights:

  • Mesh is expected to register the fastest CAGR of 5.8% over the forecast period owing to its advanced technology that provides fast and highly effective drug delivery when compared to that of a usual nebulizer.
  • The asthma segment dominated the market in 2023 and accounted for a market share of 40.0% driven by the high prevalence of asthma, which requires regular and effective administration of drugs for disease management.
  • The hospitals and clinics segment dominated the market in 2023. The hospitals and clinics provide a controlled environment with physicians trained to administer nebulized drugs, especially for critical cases or patients who require intensive care.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Nebulizer Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. U.S. Nebulizer Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. U.S. Nebulizer Market: Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. U.S. Nebulizer Market: Type Movement Analysis, 2023 & 2030 (USD Million)
  • 4.3. Jet
    • 4.3.1. Jet Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Mesh
    • 4.4.1. Mesh Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Ultrasonic
    • 4.5.1. Ultrasonic Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. U.S. Nebulizer Market: Application Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. U.S. Nebulizer Market: Application Movement Analysis, 2023 & 2030 (USD Million)
  • 5.3. COPD
    • 5.3.1. COPD Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Asthma
    • 5.4.1. Asthma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Others
    • 5.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. U.S. Nebulizer Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. U.S. Nebulizer Market: End Use Movement Analysis, 2023 & 2030 (USD Million)
  • 6.3. Hospitals and Clinics
    • 6.3.1. Hospitals and Clinics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Emergency Centers
    • 6.4.1. Emergency Centers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Others
    • 6.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis by Key Market Participants
  • 7.2. Company Categorization
  • 7.3. Company Heat Map Analysis
  • 7.4. Company Profiles
    • 7.4.1. OMRON Healthcare, Inc.
      • 7.4.1.1. Participant's Overview
      • 7.4.1.2. Financial Performance
      • 7.4.1.3. Product Benchmarking
      • 7.4.1.4. Recent Developments/ Strategic Initiatives
    • 7.4.2. GE Healthcare
      • 7.4.2.1. Participant's Overview
      • 7.4.2.2. Financial Performance
      • 7.4.2.3. Product Benchmarking
      • 7.4.2.4. Recent Developments/ Strategic Initiatives
    • 7.4.3. Koninklijke Philips N.V.
      • 7.4.3.1. Participant's Overview
      • 7.4.3.2. Financial Performance
      • 7.4.3.3. Product Benchmarking
      • 7.4.3.4. Recent Developments/ Strategic Initiatives
    • 7.4.4. Allied Healthcare
      • 7.4.4.1. Participant's Overview
      • 7.4.4.2. Financial Performance
      • 7.4.4.3. Product Benchmarking
      • 7.4.4.4. Recent Developments/ Strategic Initiatives
    • 7.4.5. Vectura Group Plc.
      • 7.4.5.1. Participant's Overview
      • 7.4.5.2. Financial Performance
      • 7.4.5.3. Product Benchmarking
      • 7.4.5.4. Recent Developments/ Strategic Initiatives
    • 7.4.6. PARI Respiratory Equipment, Inc.
      • 7.4.6.1. Participant's Overview
      • 7.4.6.2. Financial Performance
      • 7.4.6.3. Product Benchmarking
      • 7.4.6.4. Recent Developments/ Strategic Initiatives
    • 7.4.7. Aerogen
      • 7.4.7.1. Participant's Overview
      • 7.4.7.2. Financial Performance
      • 7.4.7.3. Product Benchmarking
      • 7.4.7.4. Recent Developments/ Strategic Initiatives
    • 7.4.8. DeVilbiss Healthcare LLC
      • 7.4.8.1. Participant's Overview
      • 7.4.8.2. Financial Performance
      • 7.4.8.3. Product Benchmarking
      • 7.4.8.4. Recent Developments/ Strategic Initiatives
    • 7.4.9. Briggs Healthcare
      • 7.4.9.1. Participant's Overview
      • 7.4.9.2. Financial Performance
      • 7.4.9.3. Product Benchmarking
      • 7.4.9.4. Recent Developments/ Strategic Initiatives
    • 7.4.10. Beurer GmBH
      • 7.4.10.1. Participant's Overview
      • 7.4.10.2. Financial Performance
      • 7.4.10.3. Product Benchmarking
      • 7.4.10.4. Recent Developments/ Strategic Initiatives